SRPT vs VOR

Sarepta's 10x growth potential remains highly challenged by persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance ($1.2B-$1.4B from $1.86B in 2025). While recent initial Phase 1/2 siRNA data shows promise for future pipeline diversification and an sNDA for traditional approval of existing PMOs is planned, these bright...

Vor Biopharma presents a compelling high-risk, high-reward opportunity, demonstrating 10x growth potential within 3-5 years if key clinical milestones are met. The company's 'Mine-Resistant™' platform for AML is highly innovative, aiming to enable more potent targeted therapies. A major positive development since the last analysis is the successful securing of a $110 million private placement in D...